Prevalence of Primary Cutaneous Lymphomas: A Cross-Sectional Study Using SEER Database in the United States Melissa Marchan-Martinez, BS1, Shangyi Fu BS2,3, Vivian Rojas BS1, Ibeth Caceres, BS2 Diana Bonilla, MS1, Danny Huynh BS4
Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program Neil J. Korman,1 Thierry Passeron,2 Kenneth B. Gordon,3 Yukari Okubo,4 Jerry Bagel,5 Howard Sofen,6 Richard B. Warren,7 Neal Bhatia,8 Lynda Spelman,9 Kevin Winthrop,10 Lauren Hippeli,11 Renata M. Kisa,11 Subhashis Banerjee,11 Diamant Thaçi12
Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials April W. Armstrong,1 Mark Lebwohl,2 Richard B. Warren,3 Howard Sofen,1,4 Shinichi Imafuku,5 Mamitaro Ohtsuki,6 Lynda Spelman,7 Thierry Passeron,8 Kim A. Papp,9 Renata M. Kisa,10 Victoria Berger,10 Eleni Vritzali,10, Kim Hoyt,10 Matthew J. Colombo,10 Subhashis Banerjee,10 Bruce Strober,11 Diamant Thaçi,12 Andrew Blauvelt13
Survey of the Prices of Topical Compounded Medications for Alopecia in the Tri-State Area Janet Choi BS1, Kelly Hawkins BS1, Eliza Balazic BS1, Shaveonte Graham BA2, Chesahna Kindred MD3, Kseniya Kobets MD, MHS1
Atopic Dermatitis: Impact on Patient and Family Quality of Life Cassidy Nguyen, BS1, Sasha D. Jaquez, PhD2,3,4; Courtney N. Haller, MD1; Raquel L. Bruinsma, MD1; Gregory Arbet, MS5; Emily A. Croce, PhD, CPNP-PC, RN2,6,7; Katherine R Sebastian, RN, MPH1; Lucia Z. Diaz, MD1,2,8
Post-marketing surveillance of adalimumab-adaz in psoriasis patients: A comparative analysis of adverse events in FDA drug-labeling and FDA Adverse Event Reporting System Sara Osborne, BS,1 Olivia Kam, BA,2 Raquel Wescott, BS,3 Shivani Thacker, DO,4 Jashin Wu, MD,5
The Correlation between Hidradenitis Suppurativa and Irritable Bowel Diseases: A Systematic Review Zachrieh Alhaj, BS/BA1*, Zaid Almubaid, BSA1*, Gengi Kleto, BS1*, Vivian Nicole, BS1*, Samsudeen Iyamah, BS/MS 1*, Juan Pinto-Cuberos, MD2*, Ayezel Munoz Gonzalez, MD2* John Sealy School of Medicine1, UTMB Department of Dermatology2, The University of Texas Medical Branch, Galveston, TX,